- Home
- MYGN vs GETY Comparison
MYGN vs GETY Comparison
Compare MYGN & GETY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- GETY
- Stock Information
- Founded
- MYGN 1991
- GETY 1995
- Country
- MYGN United States
- GETY United States
- Employees
- MYGN N/A
- GETY N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GETY Industrial Machinery/Components
- Sector
- MYGN Health Care
- GETY Industrials
- Exchange
- MYGN Nasdaq
- GETY Nasdaq
- Market Cap
- MYGN 2.0B
- GETY 1.6B
- IPO Year
- MYGN 1995
- GETY N/A
- Fundamental
- Price
- MYGN $15.25
- GETY $3.14
- Analyst Decision
- MYGN Buy
- GETY Strong Buy
- Analyst Count
- MYGN 12
- GETY 4
- Target Price
- MYGN $27.64
- GETY $5.61
- AVG Volume (30 Days)
- MYGN 990.7K
- GETY 400.0K
- Earning Date
- MYGN 11-07-2024
- GETY 11-07-2024
- Dividend Yield
- MYGN N/A
- GETY N/A
- EPS Growth
- MYGN N/A
- GETY N/A
- EPS
- MYGN N/A
- GETY 0.13
- Revenue
- MYGN $823,600,000.00
- GETY $917,902,000.00
- Revenue This Year
- MYGN $13.85
- GETY $3.79
- Revenue Next Year
- MYGN $7.73
- GETY $2.37
- P/E Ratio
- MYGN N/A
- GETY $23.28
- Revenue Growth
- MYGN 12.15
- GETY N/A
- 52 Week Low
- MYGN $15.18
- GETY $2.88
- 52 Week High
- MYGN $29.30
- GETY $5.77
- Technical
- Relative Strength Index (RSI)
- MYGN 16.18
- GETY 31.39
- Support Level
- MYGN $16.86
- GETY $3.40
- Resistance Level
- MYGN $19.60
- GETY $3.56
- Average True Range (ATR)
- MYGN 1.17
- GETY 0.23
- MACD
- MYGN -0.25
- GETY -0.12
- Stochastic Oscillator
- MYGN 0.90
- GETY 2.14
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About GETY Getty Images Holdings Inc.
Getty Images Holdings Inc is engaged in the core mission of bringing the world's creative and editorial visual content solutions to its customers to engage their audiences. the company has developed market enhancements across e-commerce, content subscriptions, user-generated content, diverse and inclusive content, and proprietary research alongside investment in its technology platform, which includes artificial intelligence and machine learning-driven search functionality and image editing and integrated APIs, to become a trusted industry leader in the visual content. Geographically the company operates in the Americas, Europe, the Middle East, Africa, and Asia-Pacific, out of which a majority of its revenue is generated from the Americas.